NOVEL BIOMARKERS and CARDIOVASCULAR DISEASE Nathan D Wong, PhD, FACC Professor and Director Heart Disease Prevention Program University of California, Irvine
Beyond Cholesterol: Predicting Cardiovascular Risk In the 21 st Century Cardiovascular Risk Lipids HTN Diabetes Behavioral Hemostatic Thrombotic Inflammatory Genetic
Inflammation and Atherosclerosis
Inflammation may determine plaque stability
- Unstable plaques have increased leukocytic infiltrates
- T cells, macrophages predominate rupture sites
- Cytokines and metalloproteinases influence both stability and degradation of the fibrous cap
Lipid lowering may reduce plaque inflammation
- Decreased macrophage number
- Decreased expression of collagenolytic enzymes (MMP-1)
- Increased interstitial collagen
- Decreased expression of E-selectin
- Reduced calcium deposition
Libby P. Circulation 1995;91:2844-2850. Ross R. N Engl J Med 1999;340:115-126.
Is there clinical evidence that inflammatory markers predict future coronary events and provide additional predictive information beyond traditional risk factors?
Evaluating Novel Risk Factors for CAD
Consistency of prospective data
Strength of association
Independence of association
Improve predictive value
Thrombosis and Cardiovascular Risk
Thrombus formation is a crucial factor in the precipitation of unstable angina or myocardial infarction, as well as occlusion during or following angioplasty.
Often preceded by platelet aggregation and activation of the coagulation system.
A thrombus may develop at sites of only mild to moderate coronary stenosis. The majority of coronary events occur where there is less than 70% stenosis.
Occlusive coronary thrombosis plays a role in over 80% of myocardial infarctions and about 95% of sudden death victims.
Fibrinogen and Atherosclerosis
Essential component of platelet aggregation
Relates to fibrin deposited and the size of the clot
Increases plasma viscosity
May also have a proinflammatory role
Measurement of fibrinogen, incl. Test variability, remains difficult.
No known therapies to selectively lower fibrinogen levels in order to test efficacy in CHD risk reduction via clinical trials.
Fibrinogen and CHD Risk: Epidemiologic Studies
Recent meta-analysis of 18 studies involving 4018 CHD cases showed a relative risk of CHD of 1.8 (95% CI 1.6-2.0) comparing the highest vs lowest tertile of fibrinogen levels (mean .35 vs. .25 g/dL)
ARIC study in 14,477 adults aged 45-64 showed relative risks of 1.8 in men and 1.5 in women, attenuated to 1.5 and 1.2 after risk factor adjustment.
Scottish Heart Health Study of 5095 men and 4860 women showed fibrinogen to be an independent risk factor for new events--RRs 2.2-3.4 for coronary death and all-cause mortality.
Fibrinogen and CHD Risk Factors
Fibrinogen levels increase with age and body mass index, and higher cholesterol levels
Smoking can reversibly elevated fibrinogen levels, and cessation of smoking can lower fibrinogen.
Those who exercise, eat vegetarian diets, and consume alcohol have lower levels. Exercise may also lower fibrinogen and plasma viscosity.
Studies also show statin-fibrate combinations (simvastatin-ciprofibrate) and estrogen therapy to lower fibrinogen.
Other Thrombotic Factors and CHD
Mixed reports of coagulation factor VIIc in cardiovascular disease. PROCAM study showed no association with CHD events, CHS also showed no relation to subclinical CVD.
Endogenous tissue-type plasminogen activator (tPA) shown in some studies to relate to increased cardiovascular risk--Physician’s Health Study showed RR for MI 2.8, stroke 3.5 in those in 5th vs. 1st quintile of tPA.
Plasminogen activitor inhibitor type 1 (PAI-1) shown associated with increased cardiovascular risk, esp in diabetic patients.
Aspirin and Cardiovascular Risk: Clinical Trial Evidence for Primary Prevention
US Physician’s Health Study- 22,071 male physicians - 44% reduction in MI risk, 13% nonsignificant increase in risk of stroke
British Doctor’s Study of 5139 male physicians showed nonsignificant 3% reduction in MI risk,13% nonsignificant increase in stroke
Hypertension Optimal Treatment (HOT) study among 18,790 pts w/htn showed 15% reduction in CVD events, 36% reduction in MI
Women’s Health Study (n=39,876 women aged 45+) randomized to 100 mg asprin/day vs placebo, 10 years follow-up – results recently released and asprin preventive only for stroke (17% reduction overall, p=0.04; 24% ischemic stroke, p<.001); nonfatal MI RR=1.02, CVD death 0.95, ns) (NEJM 2005; 352: 1366-8).
Aspirin and Cardiovascular Risk: Clinical Trial Evidence for Secondary Prevention
Antiplatelet Trialists Collaboration of 54,000 patients with cardiovascular disease (10 trials post-MI) showed 31% reduction in MI, 42% reduction in stroke, 13% reduction in total vascular mortality
International Study of Infarct Survival of 17,187 pts w/evolving MI showed 49% reduction in reinfarction, 26% reduction in nonfatal stroke, and 23% reduction in total vascular mortality
Antiplatelet Therapy: Targets Collagen Thrombin TXA 2 ADP (Fibrinogen Receptor) ADP = adenosine diphosphate, TXA 2 = thromboxane A 2 , COX = cyclooxygenase clopidogrel bisulfate TXA 2 phosphodiesterase ADP Gp IIb/IIIa Activation COX ticlopidine hydrochloride aspirin Gp 2b/3a Inhibitors dipyridamole Schafer AI . Am J Med 1996;101:199–209
Antiplatelet Therapy: Common Oral Agents 1 Topol EJ et al. Circulation. 2003;108:399-406 2 Diener H-C et al. Lancet 2004;364;331-7 3 Plavix® package insert. www.sanofi-synthelabo.us 4 Peters RJ et al. Circulation 2003;108:1682-7 5 Hass WK. NEJM 1989;321:501-7 6 Urban P. Circulation. 1998;98:2126-32 7 Ticlid® package insert. www.rocheusa.com * Clopidogrel is generally given preference over Ticlopidine because of a superior safety profile Thienopyridine Thienopyridine Salicylate Class 1.0% alone 5 1.7-5.5% w/ ASA 6,7 1.0-3.7% alone 2,3 3.0-4.9% w/ ASA 4 2.4-3.3% 1 Major Bleeding Risk (%) 250 mg twice daily 75 mg daily 75-325 mg daily Maintenance Dose Active Drug Pro-Drug Active Drug Formulation Ticlid® Plavix® Aspirin Trade Name Ticlopidine hydrochloride* Clopidogrel bisulfate* Acetylsalicylic acid (ASA)
Aspirin: Mechanism of Action Membrane Phospholipids ARACHIDONIC ACID Prostaglandin H 2 COX-1 Thromboxane A 2 Platelet Aggregation Vasoconstriction Prostacyclin Platelet Aggregation Vasodilitation Aspirin
Aspirin Recommendations Aspirin (75-162 mg daily) for intermediate risk men with a 10 year risk of CHD > 10%. Aspirin (75-162 mg daily) for intermediate risk women with a 10 year risk of CHD > 10%. Aspirin for low risk women with a 10 year risk of CHD<10%. Aspirin (75-325 mg daily) for those with known CHD. Primary Prevention Secondary Prevention I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III B
Rader, NEJM 2000; 343: 1181.
CRP vs hs-CRP
CRP is an acute-phase protein produced by the liver in response to cytokine production (IL-6, IL-1, tumor necrosis factor) during tissue injury, inflammation, or infection.
Standard CRP tests determine levels which are increased up to 1,000-fold in response to infection or tissue destruction, but cannot adequately assess the normal range
High-sensitivity CRP (hs-CRP) assays (i.e. Dade Behring) detect levels of CRP within the normal range, levels proven to predict future cardiovascular events.
Potential Mechanisms Linking CRP to Atherothrombosis
Confounding by cigarette consumption
Innocent bystander - Acute phase response
Cytokine surrogate - IL-6, TNF- , IL-1
Direct effects of CRP - Innate immunity - Complement activation - CAM induction
Prior infection - Chlamydia, H pylori, CMV
Marker for subclinical atherosclerosis - EBCT / IMT / ABI
Marker for insulin resistance/ obesity
Marker for endothelial dysfunction
Marker for dysmetabolic syndrome
Marker for plaque vulnerability
hs-CRP and Risk of Future MI in Apparently Healthy Men P <0.001 P <0.001 P =0.03 Quartile of hs-CRP P Trend <0.001 Relative Risk of MI Ridker et al, N Engl J Med. 1997;336:973–979. 1 2 3 4 0 1 2 3
hs-CRP and Risk of Future Stroke in Apparently Healthy Men P <0.02 P =0.02 Relative Risk of Ischemic Stroke P Trend <0.03 Ridker et al, N Engl J Med. 1997;336:973–979. Quartile of hs-CRP 0 1 2 1 2 3 4
hs-CRP as a Risk Factor For Future CVD : Primary Prevention Cohorts 0 1.0 2.0 3.0 4.0 5.0 6.0 Kuller MRFIT 1996 CHD Death Ridker PHS 1997 MI Ridker PHS 1997 Stroke Tracy CHS/RHPP 1997 CHD Ridker PHS 1998,2001 PAD Ridker WHS 1998,2000,2002 CVD Koenig MONICA 1999 CHD Roivainen HELSINKI 2000 CHD Mendall CAERPHILLY 2000 CHD Danesh BRHS 2000 CHD Gussekloo LEIDEN 2001 Fatal Stroke Lowe SPEEDWELL 2001 CHD Packard WOSCOPS 2001 CV Events* Ridker AFCAPS 2001 CV Events* Rost FHS 2001 Stroke Pradhan WHI 2002 MI,CVD death Albert PHS 2002 Sudden Death Sakkinen HHS 2002 MI Relative Risk (upper vs lower quartile) Ridker PM. Circulation 2003;107:363-9
hs-CRP Adds to Predictive Value of TC:HDL Ratio in Determining Risk of First MI Total Cholesterol:HDL Ratio Ridker et al, Circulation. 1998;97:2007–2011. hs-CRP Relative Risk
Risk Factors for Future Cardiovascular Events: WHS 0 1.0 2.0 4.0 6.0 Lipoprotein(a) Homocysteine IL-6 TC LDLC sICAM-1 SAA Apo B TC: HDLC hs-CRP hs-CRP + TC: HDLC Relative Risk of Future Cardiovascular Events Ridker et al, N Engl J Med. 2000;342:836-43
1.00 0.99 0.98 0.97 0.96 0.00 0 2 4 6 8 Years of Follow-up Low CRP-low LDL Low CRP-high LDL High CRP-low LDL High CRP-high LDL CV Event-Free Survival Using Combined hs-CRP and LDL-C Measurements Ridker et al, N Engl J Med. 2002;347:1157-1165. Probability of Event-free Survival Median LDL 124 mg/dl Median CRP 1.5mg/l
hs-CRP Adds Prognostic Information at all Levels of LDL-C and at all Levels of the Framingham Risk Score 0 - 1 25 20 15 10 5 0 Relative risk Multivariable relative risk 2 - 4 5 - 9 10-20 130 - 160 <130 >160 Framingham estimate of 10-year risk (%) LDL cholesterol (mg/dL) C-Reactive Protein (mg/L) C-Reactive Protein (mg/L) 1 0 2 3 <1.0 1.0 -3.0 >3.0 Ridker et al, N Engl J Med. 2002;347:1557. <1.0 1.0 -3.0 >3.0
Plasma hs-CRP Levels According to Severity of the Metabolic Syndrome 0 1 2 3 4 5 0 2 4 6 8 C-reactive protein (mg/L) Number of Components of the Metabolic Syndrome Ridker et al, Circulation 2003;107:391-7
0 2 4 6 8 Years of Follow-Up 0.95 0.96 0.97 0.98 0.99 1.00 CVD Event-Free Survival Probability CRP <1 mg/L CRP 1-3 mg/L CRP >3 mg/L Event Free Survival According to hs-CRP Levels: Analysis Limited to Participants with Metabolic Syndrome at Baseline Ridker et al, Circulation 2003;107:391-7
AHA / CDC Scientific Statement Markers of Inflammation and Cardiovascular Disease: Applications to Clinical and Public Health Practice Circulation January 28, 2003 “Measurement of hs-CRP is an independent marker of risk and may be used at the discretion of the physician as part of global coronary risk assessment in adults without known cardiovascular disease. Weight of evidence favors use particularly among those judged at intermediate risk by global risk assessment”.
Clinical Application of hs-CRP for Cardiovascular Risk Prediction 1 mg/L 3 mg/L 10 mg/L Low Risk Moderate Risk High Risk Acute Phase Response Ignore Value, Repeat Test in 3 weeks >100 mg/L Ridker PM. Circulation 2003;107:363-9
Is there clinical evidence that inflammation can be modified by preventive therapies?
Elevated CRP Levels in Obesity: NHANES 1988-1994 Visser M et al. JAMA 1999;282:2131-2135. Normal Percent with CRP 0.22 mg/dL Overweight Obese
Effects of Weight Loss on CRP Concentrations in Obese Healthy Women
83 women (mean BMI 33.8, range 28.2-43.8 kg/m 2 ) placed on very low fat, energy-restricted diet (6.0 MJ, 15% fat) for 12 weeks
Baseline CRP positively associated with BMI (r=0.281, p=0.01)
CRP reduced by 26% (p<0.001)
Average weight loss 7.9 kg, associated with change in CRP
Change in CRP correlated with change in TC (r=0.240, p=0.03) but not changes in LDL-C, HDL-C, or glucose
At 12 weeks, CRP concentration highly correlated with TG (r=0.287, p=0.009), but not with other lipids or glucose
Heilbronn LK et al. Arterioscler Thromb Vasc Biol 2001;21:968-970.
Effect of HRT on hs-CRP: the PEPI Study 3.0 2.0 1.0 hs-CRP (mg/dL) Months 0 12 36 Cushman M et al. Circulation 1999;100:717-722. 1999 Lippincott Williams & Wilkins. CEE + MPA cyclic CEE + MPA continuous CEE + MP CEE Placebo
Long-Term Effect of Statin Therapy on hs-CRP: Placebo and Pravastatin Groups Pravastatin Placebo Median hs-CRP Concentration (mg/dL) -21.6% ( P =0.004) 0.18 0.19 0.20 0.21 0.22 0.23 0.24 0.25 Baseline 5 Years Ridker et al, Circulation. 1999;100:230-235.
Effect of Statin Therapy on hs-CRP Levels at 6 Weeks hs-CRP (mg/L) Jialal I et al. Circulation 2001;103:1933-1935. 2001 Lippincott Williams & Wilkins. 6 5 4 3 2 1 0 Baseline Prava (40 mg/d) Simva (20 mg/d) Atorva (10 mg/d) *p<0.025 vs. Baseline * * *
A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial Paul Ridker*, Eleanor Danielson, Francisco Fonseca*, Jacques Genest*, Antonio Gotto*, John Kastelein*, Wolfgang Koenig*, Peter Libby*, Alberto Lorenzatti*, Jean MacFadyen, Borge Nordestgaard*, James Shepherd*, James Willerson, and Robert Glynn* on behalf of the JUPITER Trial Study Group An Investigator Initiated Trial Funded by AstraZeneca, USA * These authors have received research grant support and/or consultation fees from one or more statin manufacturers, including Astra-Zeneca. Dr Ridker is a co-inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to Dade-Behring and AstraZeneca.
In 2001, in an hypothesis generating analysis of apparently healthy individuals in the AFCAPS / TexCAPS trial*, we observed that those with low levels of both LDL and hsCRP had extremely low vascular event rates and that statin therapy did not reduce events in this subgroup (N=1,448, HR 1.1, 95% CI 0.56-2.08). Thus, a trial of statin therapy in patients with low cholesterol and low hsCRP would not only be infeasible in terms of power and sample size, but would be highly unlikely to show clinical benefit. In contrast, we also observed within AFCAPS/TexCAPS that among those with low LDL but high hsCRP , vascular event rates were just as high as rates among those with overt hyperlipidemia, and that statin therapy significantly reduced events in this subgroup (N=1,428, HR 0.6, 95% CI 0.34-0.98). *Ridker et al N Engl J Med 2001;344:1959-65
However, while intriguing and of potential public health importance, the observation in AFCAPS/TexCAPS that statin therapy might be effective among those with elevated hsCRP but low cholesterol was made on a post hoc basis. Thus, a large-scale randomized trial of statin therapy was needed to directly test this hypotheses. Ridker et al, New Engl J Med 2001;344:1959-65 Low LDL, Low hsCRP Low LDL, High hsCRP Statin Effective Statin Not Effective 1.0 2.0 0.5 [A] [B] Low LDL, Low hsCRP Low LDL, High hsCRP Statin Effective Statin Not Effective 1.0 2.0 0.5 AFCAPS/TexCAPS Low LDL Subgroups RR
To investigate whether rosuvastatin 20 mg compared to placebo would decrease the rate of first major cardiovascular events among apparently healthy men and women with LDL < 130 mg/dL (3.36 mmol/L) who are nonetheless at increased vascular risk on the basis of an enhanced inflammatory response, as determined by hsCRP > 2 mg/L. To enroll large numbers of women and individuals of Black or Hispanic ethnicity, groups for whom little data on primary prevention with statin therapy exists. J ustification for the U se of statins in P revention: an I ntervention T rial E valuating R osuvastatin Ridker et al NEJM 2008
Rosuvastatin 20 mg (N=8901) MI Stroke Unstable Angina CVD Death CABG/PTCA JUPITER Multi-National Randomized Double Blind Placebo Controlled Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among Individuals With Low LDL and Elevated hsCRP 4-week run-in Ridker et al, Circulation 2003;108:2292-2297. No Prior CVD or DM Men > 50, Women > 60 LDL <130 mg/dL hsCRP > 2 mg/L JUPITER Trial Design Placebo (N=8901) Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica, Denmark, El Salvador, Estonia, Germany, Israel, Mexico, Netherlands, Norway, Panama, Poland, Romania, Russia, South Africa, Switzerland, United Kingdom, Uruguay, United States, Venezuela
JUPITER Baseline Clinical Characteristics Rosuvastatin Placebo (N = 8901) (n = 8901) Age, years (IQR) 66.0 (60.0-71.0) 66.0 (60.0-71.0) Female, N (%) 3,426 (38.5) 3,375 (37.9) Ethnicity, N (%) Caucasian 6,358 (71.4) 6,325 (71.1) Black 1,100 (12.4) 1,124 (12.6) Hispanic 1,121 (12.6) 1,140 (12.8) Blood pressure, mm (IQR) Systolic 134 (124-145) 134 (124-145) Diastolic 80 (75-87) 80 (75-87) Smoker, N (%) 1,400 (15.7) 1,420 (16.0) Family History, N (%) 997 (11.2) 1,048 (11.8) Metabolic Syndrome, N (%) 3,652 (41.0) 3,723 (41.8) Aspirin Use, N (%) 1,481 (16.6) 1,477 (16.6) All values are median (interquartile range) or N (%) Ridker et al NEJM 2008
JUPITER Primary Trial Endpoint : MI, Stroke, UA/Revascularization, CV Death Placebo 251 / 8901 Rosuvastatin 142 / 8901 HR 0.56, 95% CI 0.46-0.69 P < 0.00001 Number Needed to Treat (NNT 5 ) = 25 - 44 % 0 1 2 3 4 0.00 0.02 0.04 0.06 0.08 Cumulative Incidence Number at Risk Follow-up (years) Rosuvastatin Placebo 8,901 8,631 8,412 6,540 3,893 1,958 1,353 983 544 157 8,901 8,621 8,353 6,508 3,872 1,963 1,333 955 534 174 Ridker et al NEJM 2008
JUPITER Grouped Components of the Primary Endpoint HR 0.53, CI 0.40-0.70 P < 0.00001 Rosuvastatin Placebo Myocardial Infarction, Stroke, or Cardiovascular Death Arterial Revascularization or Hospitalization for Unstable Angina HR 0.53, CI 0.40-0.69 P < 0.00001 0 1 2 3 4 0.00 0.01 0.02 0.03 0.04 0.05 0.06 Cumulative Incidence Follow-up (years) 0 1 2 3 4 0.00 0.01 0.02 0.03 0.04 0.05 Cumulative Incidence Follow-up (years) Placebo Rosuvastatin - 47 % - 47 % Ridker et al NEJM 2008
JUPITER Individual Components of the Primary Endpoint *Nonfatal MI, nonfatal stroke, revascularization, unstable angina, CV death Endpoint Rosuvastatin Placebo HR 95%CI P Primary Endpoint* 142 251 0.56 0.46-0.69 <0.00001 Non-fatal MI 22 62 0.35 0.22-0.58 <0.00001 Any MI 31 68 0.46 0.30-0.70 <0.0002 Non-fatal Stroke 30 58 0.52 0.33-0.80 0.003 Any Stroke 33 64 0.52 0.34-0.79 0.002 Revascularization or Unstable Angina 76 143 0.53 0.40-0.70 <0.00001 MI, Stroke, CV Death 83 157 0.53 0.40-0.69 <0.00001 Ridker et al NEJM 2008
JUPITER Primary Endpoint – Subgroup Analysis I 0.25 0.5 1.0 2.0 4.0 Rosuvastatin Superior Rosuvastatin Inferior Men Women Age < 65 Age > 65 Smoker Non-Smoker Caucasian Non-Caucasian USA/Canada Rest of World Hypertension No Hypertension All Participants N P for Interaction 11,001 0.80 6,801 8,541 0.32 9,261 2,820 0.63 14,975 12,683 0.57 5,117 6,041 0.51 11,761 10,208 0.53 7,586 17,802 Ridker et al NEJM 2008
JUPITER Primary Endpoint – Subgroup Analysis II 0.25 0.5 1.0 2.0 4.0 Rosuvastatin Superior Rosuvastatin Inferior Family HX of CHD No Family HX of CHD BMI < 25 kg/m 2 BMI 25-29.9 kg/m BMI > 30 kg/m Metabolic Syndrome No Metabolic Syndrome Framingham Risk < 10% Framingham Risk > 10% hsCRP > 2 mg/L Only All Participants N P for Interaction 2,045 0.07 15,684 4,073 0.70 7,009 6,675 7,375 0.14 10,296 8,882 0.99 8,895 6,375 17,802 2 2 hsCRP > 2 mg/L Only 6,375 Ridker et al NEJM 2008
JUPITER Adverse Events and Measured Safety Parameters Event Rosuvastatin Placebo P Any SAE 1,352 (15.2) 1,337 (15.5) 0.60 Muscle weakness 1,421 (16.0) 1,375 (15.4) 0.34 Myopathy 10 (0.1) 9 (0.1) 0.82 Rhabdomyolysis 1 (0.01)* 0 (0.0) -- Incident Cancer 298 (3.4) 314 (3.5) 0.51 Cancer Deaths 35 (0.4) 58 (0.7) 0.02 Hemorrhagic stroke 6 (0.1) 9 (0.1) 0.44 GFR (ml/min/1.73m 2 at 12 mth) 66.8 (59.1-76.5) 66.6 (58.8-76.2) 0.02 ALT > 3xULN 23 (0.3) 17 (0.2) 0.34 Fasting glucose (24 mth) 98 (91-107) 98 (90-106) 0.12 HbA1c (% at 24 mth) 5.9 (5.7-6.1) 5.8 (5.6-6.1) 0.01 Glucosuria (12 mth) 36 (0.5) 32 (0.4) 0.64 Incident Diabetes** 270 (3.0) 216 (2.4) 0.01 *Occurred after trial completion, trauma induced. All values are median (interquartile range) or N (%) **Physician reported Ridker et al NEJM 2008
JUPITER Statins and the Development of Diabetes WOSCOPS Pravastatin HPS Simvastatin ASCOT-LLA Atorvastatin JUPITER Rosuvastatin PROVE-IT Atorvastatin VS Pravastatin 0.70 (0.50–0.98) 1.20 (0.98–1.35) 1.20 (0.91–1.44) 1.11 (0.67–1.83) 1.25 (1.05–1.54) Statin Better Statin Worse HR (95% CI) PROSPER Pravastatin 1.34 (1.06–1.68) Ridker et al NEJM 2008 0.25 0.5 1.0 2 4
JUPITER Conclusions – Efficacy I Among apparently healthy men and women with elevated hsCRP but low LDL, rosuvastatin reduced by 47 percent incident myocardial infarction, stroke, and cardiovascular death. Despite evaluating a population with lipid levels widely considered to be “optimal” in almost all current prevention algorithms, the relative benefit observed in JUPITER was greater than in almost all prior statin trials. In this trial of low LDL/high hsCRP individuals who do not currently qualify for statin therapy, rosuvastatin significantly reduced all-cause mortality by 20 percent. Ridker et al NEJM 2008
JUPITER Implications for Primary Prevention Among men and women age 50 or over : If diabetic, treat If LDLC > 160 mg/dL, treat If hsCRP > 2 mg/L, treat A simple evidence based approach to statin therapy for primary prevention. Ridker et al NEJM 2008
Inflammatory and Infections Agents in CHD
Belgian epidemiologic study included 446 of 16307 male workers aged 35-39 who had evidence of CHD vs. 892 controls.
CRP, but none of the infectious agents (H. pylori, C. pneumoniae, CMV, and EBV) were associated with CHD, even after adjustment for other risk factors.
De Backer et al. Atherosclerosis 2002; 160: 457-63.
Infection and CHD - is there a connection?
Local or systemic infections resulting from gram negative bacteria such as Chlamydia pneumoniae and Helicobacter pylori, including cytomegalovirus (CMV) have been implicated in atheroscelosis
While several case control studies have shown increased titers of C.pneumoniae and H. Pylori in those with vs. without CHD, convincing evidence from prospective studies is lacking.
Prospective Studies of CHD and Infectious Pathogens
Physician’s Health Study (nested case-control) shows RR 1.1 (0.8-1.5) for C. Pneumoniae, 0.94 (0.7-1.2) for cytomegalovirus, and 0.72 (0.6-0.9) for Herpes simplex virus.
H. pylori also shows mixed results. Whincup showed a nonsignificant 1.3 OR when adjusted for other risk factors, the large ARIC study showed no relation, and the Caerphilly Prospective study showed RR=1.05 in 1796 men followed 14 years.
Other Studies of Infectious Agents
In South Asian persons with CHD vs. controls, C. pneumoniae specific IgG antibody was seropositive in similar proportions; risk factors appeared to mediate any relations (Mendis et al. Int J Cardiol 2001; 79: 191-6).
Cross-sectional survey of 704 individuals of C. pneumoniae and CMV with risk factors did nto show significant associations (Danesh et al., J Cardiovasc Risk 1999; 6: 387-90).
Meta-analysis of 24 articles involving H. pylori infection and CHD showed a pooled odds ratio of 1.55 (95% CI: 1.38-1.74) (p<0.001), suggested a weak relation, but high hetrogeneity between studies precludes clear demonostration (Pellicano et al., Eur J Epidemiol 1999; 15: 611-9).
ARIC Study failed to show clear relation between IgG antibodies for C. pneumoniae and incident CHD occurring over average 3.3 years. (Nieto et al. Am J Epidemiol 1999; 150: 149-56).
Clinical Trial Evidence for Antibiotic Treatment and Prevention of CVD
ACADEMIC Study of 302 patients with CHD seropositive to C. Pneumoniae randomized to azithromycin 500 mg/wk or placebo for 3 months showed no significant treatment difference (HR=0.89, p=0.74) for recurrent events (Muhlestein et al., Circulation 2000; 102: 1755-60).
AZACS Multicenter study of 1439 pts with unstable angina randomized to 250 mg azithromycin/day for up to 6 months showed no significant benefit for death, recurrent MI, or recurrent ischemia (Cercek et al., Lancet 2003; 361: 809-13).
WIZARD trial of 7,747 pts post-MI randomized to 12 week of therapy with azithromycin or placebo showed no significant reduction in reinfarction, revascularization, hospitalization for angina, or death (O’Connor et al., JAMA 2003; 290: 1459-66).
Infectious Agents and the Future
Individuals with greater infectious burdens may be at greater risk, because they are older, have poorer health habits, less access to care.
Observed associations often may be due to selection biases or confounding from age and other factors
Prospective clinical trials under way examining role of certain antibiotics such as azithromycin on reduction of recurrent events in CHD patients.
Until these data are available, no role for measurement or treatment of infectious burden.
Multiple Biomarkers for the Prediction of First CVD Events and Death (Wang TJ et al., NEJM 2006; 355: 2631-9)
10 biomarkers examined in 3209 pts of the Framingham Heart Study
Adjusted HR’s per SD: BNP 1.4, CRP 1.4, albumin/creatinine 1.2, homocysteine 1.2, renin 1.5 for death, and BNP 1.25, albumin/creatinine 1.2 for CVD events
Multimarker scores in highest quintile vs. lowest two quintiles had adjusted HR for death of 4.1, p<0.001 and CVD events of 1.8, p=0.02
Only moderate increases in C-statistic seen from biomarkers over standard risk factors
Use of Multiple Biomarkers to Improve Prediction of CVD Death (Zethelius B et al., NEJM 2008; 358: 2107-16)
1135 elderly men from the Uppsala Longitudinal Study of Adult Men, mean age 71 years at baseline, 10 years median follow-up
Examined role of multiple markers reflecting myocardial cell damage—troponin I, LV dysfunction– N-T pro BNP, renal failure—cystatin C, and inflammation – CRP
C-statistic increased significantly when the four biomarkers were put in a model with established risk factors (0.77 vs. 0.66, p<0.0001) in the whole cohort and in those without CVD at baseline (0.748 vs. 0.688, p=0.03).
Among elderly men, multiple biomarkers may significantly improve risk for death from CVD causes beyond standard risk factors.